Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation
Sponsor: Institut de Recherches Internationales Servier
Listed as NCT00145925, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Institut de Recherches Internationales Servier, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
May 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — May 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut de Recherches Internationales Servier
- National Health and Medical Research Council, Australia
- The George Institute
- University of Sydney
For direct contact, visit the study record on ClinicalTrials.gov .